Cingulate Inc
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
- Ticker
- CING
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Shane J. Schaffer Pharm.D.
- Headquarters
- 1901 West 47th Place, Kansas City, KS, United States, 66205
- Employees
- 14
- Website
- cingulate.com
Metrics
Analyst Insights & forecasts
Based on information from 4 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|---|
| Actual | -$1.35 | -$0.84 | -$0.95 | -$0.45 |
| Expected | -$0.75 | -$1.55 | -$0.53 | -$0.63 |
| Surprise | -80.00% | 45.81% | -79.25% | 28.57% |
| Missed | Beat | Missed | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-9.3M | $-5.9M | -36.96% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Cingulate Inc share?
Cingulate Inc shares are currently traded for undefined per share.
02How many shares does Cingulate Inc have?
Cingulate Inc currently has 14.5M shares.
03Does Cingulate Inc pay dividends?
No, Cingulate Inc doesn't pay dividends.
04What is Cingulate Inc 52 week high?
Cingulate Inc 52 week high is $11.89.
05What is Cingulate Inc 52 week low?
Cingulate Inc 52 week low is $3.16.
06What is the 200-day moving average of Cingulate Inc?
Cingulate Inc 200-day moving average is $5.43.
07Who is Cingulate Inc CEO?
The CEO of Cingulate Inc is Dr. Shane J. Schaffer Pharm.D..
08How many employees Cingulate Inc has?
Cingulate Inc has 14 employees.
09What is the market cap of Cingulate Inc?
The market cap of Cingulate Inc is $66.3M.
10What is the P/E of Cingulate Inc?
The current P/E of Cingulate Inc is null.
11What is the EPS of Cingulate Inc?
The EPS of Cingulate Inc is -$3.51.
12What is the PEG Ratio of Cingulate Inc?
The PEG Ratio of Cingulate Inc is null.
13What do analysts say about Cingulate Inc?
According to the analysts Cingulate Inc is considered a buy.
